A Partially Blinded, Randomized, Multi-Center, Phase IV Trial to Evaluate Mechanism of Action of Anti-TNF Agents in Rheumatoid Arthritis.
Phase of Trial: Phase IV
Latest Information Update: 10 Feb 2016
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 07 Nov 2012 Planned end date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 01 May 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.